Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04189016
Other study ID # LC.002
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 2021
Est. completion date September 2021

Study information

Verified date January 2021
Source Liita Care ApS
Contact Zainab Saraj, Cand.Pharm.
Phone 0045 22268865
Email zs@liitacare.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigating nasal muco-ciliary clearance by scintigraphy


Description:

The velocity and the retention of the nasal muco-ciliary clearance is going to be investigated with a salt particle inhaler and a placebo by the method nasal scintigraphy. The hypotheses is that nasal inhalation of salt particles enhance the nasal mucociliary clearance.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 31
Est. completion date September 2021
Est. primary completion date August 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - COPD patients (all severities in chronic, stable condition) - Asthma patients (in stable condition without acute asthma symptoms) - Healthy subjects, incl. smokers (no chronic nasal, upper or lower respiratory diseases) Exclusion Criteria: - Age under 18 years - Upper respiratory tract infection / cold within the last 3 weeks and at least 3 weeks must pass from the person has become well to the examination - Allergic / non-allergic rhinitis (hay fever) - Chronic sinusitis - Acute respiratory tract infection in antibiotic therapy - Applied salt inhalation within the past month - Pregnant or breastfeeding women - Nuclear medical examination within the past month - Cannot taste saccharin

Study Design


Intervention

Device:
Inhalation from a salt particle inhaler with or without content
Inhalation from inhaler with (active) or without (placebo) content

Locations

Country Name City State
Denmark Rigshospitalet, Clin nuclear and physiolog dept. Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Liita Care ApS

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Nasal Mucociliary Clearance Change in nasal mucociliary clearance velocity (mm/min) from placebo to salt inhalation At study day 1 and 2
Primary Nasal Mucociliary Clearance Change in nasal mucociliary clearance retention (%) from placebo to salt inhalation At study day 1 and 2
Secondary Spirometry Change in FEV! from placebo to saltinhalation At the beginning and the end of study day 1 and 2
Secondary Saccharin test Change in time for saccharin transport At study day 1 and 2